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Abstract  
 
The utilization of Electrical Pulse Stimulation (EPS) has been predominantly used to study the 
physiological, cellular, and molecular responses of excitable cells such as nerve and muscle. Based on 
previous work on myotubes, non-excitable myoblasts, and non-excitable cancerous rhabdomyosarcoma 
cells, this study looks into the effects of EPS on breast cancer cells (MCF7s). My aim is to characterize the 
response of MCF7 cells to EPS and add to a working model of cell cycle arrest, autophagy, and cell death 
mediated by calcium signaling through cell cycle signaling proteins. This is based on the body of literature 
detailing the effects of EPS on excitable cell types. Ultimately, by stressing cancer cells with EPS, we can 
learn more about potential novel modes to induce mechanisms of proliferative failure. 
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Review of Literature 
1.0 Cancer 
 
The biology and physiology of living systems displays an incredible degree of order. Any alteration 
that throws off this order is definitionally a diseased state. Cancer is a vast collection of diseased states with 
multiple characteristics at every scale. On the scale of DNA, cancer is a disease of genetic instability1. On 
the cellular scale, cancer is an imbalance of cell growth and cell death. On the physiological scale cancer 
takes advantage of normal biological processes in order to perpetuate its own survival. The multilayered 
characteristics of cancer are commonly conceptualized into what is now known as the hallmarks of cancer. 
The hallmarks are not definitive but are used to help organize and characterize the vast territory that the 
disease occupies. The six hallmarks are: sustained proliferative signaling, invasion and metastasis, evasion 
of growth suppressors, resisting cell death, unregulated replication, and angiogenesis2. There also exists 
many emerging hallmarks of cancer including metabolic adaptations3 such as the Warburg effect4, evasion 
of immune destruction5, and the tumor microenvironment6. A cancerous cell can contain any number of 
these characteristics and from a harmless, undetectable cell, it can proliferate into a vast merciless disease 
that obstructs the order necessary for the physiological processes that make life possible. 
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Figure 1. The Hallmarks of Cancer. The hallmarks of Cancer are common characteristics acquired in the development of 
human cancer. Initially six hallmarks were accepted; sustained proliferative signaling, invasion and metastasis, evasion of 
growth suppressors, resisting cell death, unregulated replication, and angiogenesis1. There also exists many emerging 
hallmarks of cancer including metabolic adaptations, commonly referred to as the Warburg effect, evasion of immune 
destruction, and the tumor microenvironment2,3,4,5,6. Our understanding of these common characteristics in the development 
of cancer contributes greatly to current and future cancer therapy research.  
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1.1 Cancer therapies 
 
Cancer is by no means a new challenge, it’s a disease that even predates human existence. The earliest 
written description of cancer was written around 3000 BC in an ancient Egyptian medical text called the 
Edwin Smith Papyrus. This text described a breast cancer, which the writer concluded as a grave disease 
with no treatment7. Thankfully, advances in cancer diagnosis and treatment have improved. From 2003 to 
2012 the cancer mortality rate has consistently declined 1.5% annually8. That said, as of 2015 cancer was 
still the second highest cause of mortality worldwide9 with the lifetime risk of development estimated at 
48.4% and 37.3% for men and women, respectively10. Our modern understanding and ability to prevent, 
diagnose and treat cancer has improved, but it can be better. 
Cancer is a difficult problem because it is not a homogenous disease. Its genetic basis means it can take 
on an exceedingly large amount of combinations of mutations leading to any order and magnitude of traits. 
Not only can each cancer be individualized to each patient but the individual cells that comprise a patient’s 
tumor can also have a diversity of mutations and traits. Additionally, the genetic instability and increased 
rates of proliferation can cause mutations to continue to occur and occur more rapidly. Therefore, the 
heterogeneity, genetic instability and rapid replication of cancer creates a moving target for treatments.  
Thus, the diversity of cancer is a direct reflection of the diversity of treatments seen today. Surgery was 
the first popularized and effective course of action. De Medicina by Aulus Celsus (25 BC-AD 50) contained 
a comprehensive description of cancer for the time. In his writings Celsus argued the early and aggressive 
removal of tumors by surgery. Sometime later Rhazes of Baghdad (860-932) in his De Chirurgia noted that 
cancer surgery should not be attempted unless the cancer can be removed completely7. Although the idea 
of cells coming from cells would only be published in 185811, this insight touched upon cancers replicative 
phenotype. It also underlined that surgery, the main treatment option at the time, would often kill the patient 
before the cancer would; an unfortunate ongoing theme with even modern cancer therapies. This also 
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addresses that surgery is only effective for certain types of cancer depending on the location, size, and 
aggressiveness.  
  Chemical therapy dated as far back as the Egyptians and Greeks however its introduction to the 
academic medical world was by the chemist and physician Paracelsus (1493-1541)12. He described the use 
of minerals such as lead, mercury, zinc and arsenic (still used today for acute promyelocytic leukemia13) as 
internal treatments for cancer. It also acknowledged that these treatments were toxic and at high enough 
doses deadly. This idea from 1567 is still prevalent in modern chemotherapy. The issue of maximum 
tolerated dose (MTD) is the main crux of chemical therapy. Being administered in the blood means it is a 
systemic treatment; it affects cancerous and healthy cells alike. As we age the risk of developing cancer 
increases drastically14, at the same time the MTD of chemotherapy declines. Therefore, chemotherapy is 
the least effective on the population with the highest incidence of cancer. Additionally, the side effects of 
chemotherapy are undeniably terrible. Despite this chemo is the primary treatment option for cancer. It has 
been estimated that annually 58.4% of treatments of cancer within the US involve chemotherapy15. 
 The next most popular treatment option for cancer is radiation (57.9%)15. Radiotherapy was 
discovered soon after Rontgens accidental discovery of x-rays however it would take decades for the field 
radiology to advance. Early attempts of radiation therapy utilized x rays to treat breast cancers and radium 
seeds for the treatment of cervical cancers. By the 1960s technological advances in radiotherapy allowed 
for the precise and deep penetration of radiation16. The precision of radiotherapy limits damage to 
surrounding tissue while deeper penetrating beams allowed it to reach a wider variety of tumors. This ability 
of specificity and localization are the primary advantages of radiotherapy compared to chemotherapy 
however, due to its mechanism of action, radio-therapy also has multiple treatment related side effects. 
Ionizing radiation from radiotherapy ultimately damages DNA through the formation of free radicals. 
Breaks in DNA initiate an apoptotic signalling cascade that causes cell death for the radiated cells17. Since 
cancer is a disease of genetic instability any intervention that damages DNA has the potential to lead to 
  
 
5 
 
 
secondary malignancies18. Radiation has also been implicated with other long-term side effects including 
cardiac disease19, lung complications20, osteoporosis21 and infertility22. 
As our understanding evolves, we are forced to rethink the future of cancer therapy. In the 5000 
years since the Edwin smith papyrus was written the problem of cancer has not changed. In those years we 
have developed a complex understanding and array of tools to prevent, diagnose and treat cancer more 
effectively. As the diversity of cancer demands a diversity of treatments options, modern research has seen 
a push towards targeted and individualized therapies23. Therefore, more sensitive and sophisticated 
diagnostic techniques combined with an expansive array of targeted treatment options is the likely future 
of cancer therapy. 
2.0 Mammalian Cell Cycle  
 
How cancer, from a single cell, can proliferate into a vast disease is highly dependent on alterations 
within the cell cycle. The importance of our cells to regulate division is fundamental to preventing 
tumorigenesis. Depending on the external and internal environment the cell generally has three options: to 
divide, quiesce or die. All three options are controlled by complex signaling events within and outside of 
the cell. A cell that divides uncontrollably and or refuses to die, regardless of the external or internal stimuli, 
has lost its ability to communicate in sync with the surrounding environment. This threatens the homeostasis 
of the immediate area of growth, and if left alone will destroy the homeostasis of organ systems. To prevent 
this the cell cycle has evolved as a complex series of checks and balances to ensure cells divide when 
needed. It consists of four main stages, Gap 1 (G1), Synthesis (S), Gap 2 (G2), Mitosis and a 5th dormant 
stage termed G0 or quiescence (Fig. 2). Under the appropriate conditions, the cell will exit quiescence and 
enter G1 where cell growth and preparation for chromosome replication occurs. In S phase the cell 
duplicates its nuclear DNA and with two complete identical sets of chromosomes, the cell enters the G2 
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phase where the integrity of the genetic material is inspected. If all is well, we reach the final stage, mitosis. 
Mitosis entails chromosomal alignment, spindle formation and the eventual separation of sister chromatids. 
Although not part of the cell cycle, the separation of the plasma membrane, termed cytokinesis, leaves us 
with two new daughter cells24. 
The main driving forces of cell cycle progression are the Cyclin/CDK complexes. CDK proteins are 
constitutively expressed however, the Cyclins are cyclically expressed at very specific points during the 
cell cycle25. These Cyclin/CDK complexes are mainly inhibited by two families of proteins, the inhibitors 
of kinase 4 (INK4) and the kinase inhibiting proteins (KIP) (Fig. 2)26. Protein-protein interaction, 
phosphorylation and localization are common themes in the regulation of cyclins, CDKs, and their 
inhibitors throughout the cell cycle27. 
 Understanding how these proteins facilitate the checks and balances of cell growth and proliferation 
are central to understanding tumorigenesis, as mutations that directly affect the regulation of the cell cycle 
are the primary catalysts to the uncontrolled cell division seen in cancer1. Mutations to regulatory proteins 
that cause a continuous proliferative state, cancer, are termed oncogenes, while mutations that abolish a 
proteins function in preventing aberrant division are termed tumor suppressors. Oncogenic and tumor 
suppressor proteins involved in the regulation of cell cycle control are critical targets and areas of study in 
order to understand, prevent, and treat cancer.  
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Figure 2. Stages of the mammalian cell cycle. In G0 the cell remains quiescent. During G1 the cell begins to grow, monitor its 
environment and prepare for chromosomal replication. In S phase the chromosomes duplicate. With two sets of DNA the cell 
enters the G2 phase. In G2 the cell works to ensure the integrity of all DNA before entering Mitosis. In Mitosis we see 
chromosomal alignment and the separation of sister chromatids. Following cytokinesis, we are left with two new daughter 
cells. The main drivers of the cell cycle are the Cyclin CDK complexes. CDKs are expressed constitutively while cyclins are 
cyclically expressed depending on the phase of the cycle. The main inhibitors of the cell cycle are the INK and KIP families 
of proteins1. 
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1.2 G1/S Transition  
 
The first of the critical checkpoints within the cell cycle is the G1/S transition (Fig. 3). Under normal 
conditions a quiescent cell is able to assess the mitogenic potential of the surrounding environment such 
that when the conditions permit, mitogenic signalling cascades including the well-studied mitogen activated 
proteins kinase pathway (MAPK) will induce the transcriptional activation of cyclin D28,29. MAPK has 
special significance as it is a commonly used marker of tumorigenesis. In cancer the ability to respond 
appropriately to the mitogenic potential of the micro-environment is often lost due to the mis-regulation of 
pathways including the MAPK cascades which in cancer leads to a state of perpetual cell cycle entry30.  
Following cyclin D translation, CDK4/6 must be phosphorylated by CAK on threonine 172 and 
dephosphorylated by cdc25A on tyrosine 1531. Cyclin D CDK4/6 must then dissociate its inhibitor INK4 
which requires the binding and sequestration of p2732 or p2133, a process that not only activates the complex 
but also reduces the available pool of p27, the primary inhibitor of the Cyclin E/CDK2 complex34. With 
p27 sequestered and INK4 displaced, cyclin D CDK 4/6 phosphorylates the tumor suppressor protein 
Retinoblastoma (Rb)35. In an arrested cell the transcription factor E2F is bound to hypo-phosphorylated Rb, 
rendering E2F inactive36. Hyper-phosphorylated Rb dissociates E2F allowing it to bind to the DNA and 
transcribe gene targets necessary for S phase entry32. Gene targets include, DNA polymerase alpha, 
BRCA1, thymidine kinase and in a positive feedback loop more E2F and cyclin E37. Once formed the cyclin 
E CDK2 complex can phosphorylate its inhibitor, p27, on threonine 187  promoting the ubiquitination and 
targeting of p27 for degradation38. p27 also has additional phosphorylation sites with differing effects; on 
serine 10 phosphorylation causes nuclear export, threonine 157 results in cytosolic retention and 
phosphorylation of tyrosine 88 is able to disrupt the cyclin E/CDK2 binding pocket of p2738. p21, another 
member of the Kip family of proteins also has the ability to bind and inhibit cyclin CDK complexes. Similar 
to p27 this inhibition can be released through post translational modifications such as the phosphorylation 
of p21 on threonine 145 by the PI3k/AKT pathway30. Central to S phase entry is the cells ability to elevate 
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cyclin E levels above the threshold necessary to overcome the inhibition of inhibitors like p27 and p21. 
Once this threshold is reached the cell is able to enter into the synthesis phase. Throughout S phase cyclin 
E is ubiquitinated by Fbw7 targeting it for degradation while the next cyclin, cyclin A, begins to 
accumulate39. In S phase cyclin A binds to CDK2 and the genetic material is duplicated leading us out of 
the S phase and into G2 where the integrity of the DNA is assessed24. 
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Figure 3. G1/S phase signalling. Mitogenic signals induce the G1/S phase causing the formation of the Cyclin D cdk4/6 
complex. The full activation of this complex requires p27. Once bound to the Cyclin/cdk4/6 complex p27 is no longer 
available to inhibit cyclin E cdk2. The Cyclin D and E CDK complex both phosphorylate Rb. This phosphorylation 
dissociates the E2F transcription factor. The E2F transcription factor initiates the transcription of genes critical for DNA 
replication and S phase entry. It also induces the transcription of Cyclin E creating a positive feedback loop. P27 can also 
be phosphorylated by the Cyclin E CDK complex causing its eventual degradation. Ultimately, Cyclin E levels must reach 
a threshold to overcome the inhibition of p27 and allowing the cell to enter the S phase28-39.  
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1.3 G2/M Transition 
 
A long history of experimentation on a diversity of organisms has placed the protein kinase CDC2 
also known as CDK1 as a central point of regulatory activity in the G2/M transition. CDC2 is only active 
during the G2/M transition and is deactivated prior to entering anaphase40. It has been shown to bind with 
cyclin A or B41. Within the nucleus, once fully activated, the cyclin B CDC2 complex phosphorylates 
substrates responsible for the transcription of critical mitotic genes42. In the cytoplasm, importin a and b 
bind to cyclin B CDC2 and subsequently transport the complex into the nucleus (Fig. 4)43. This import is 
counter-balanced by the active export of the cyclin B CDC2 complex from the nucleus by the export protein 
exportin 1 (CRM1)44. In order to deny this export cyclin B must be phosphorylated on its CRM1 binding 
site mediated by CDC245 or (polo-like kinase 1) PLK146. Once Cyclin B is phosphorylated and its export 
from the nucleus is inhibited there are three additional posttranslational modifications required on CDC2 
to fully activate the Cyclin B/CDC2 complex. The CDK activating kinase (CAK) must phosphorylate 
CDC2 at  threonine 16147, furthermore, two dephosphorylations on tyrosine 14 and threonine 15 by the 
phosphatase CDC25 (B and C) are required48. The Cyclin B CDC2 complex is also rapidly activated through 
a positive feedback mechanism involving CDC2 phosphorylation of CDC2549. The fulfillment of this 
allows the activated CDK complex to phosphorylate target proteins required to drive the cell into mitosis40.  
The G2/M checkpoint ultimately functions to ensure the integrity of the DNA before entering mitosis. 
In an un-arrested cell, this transition accounts for only 15% of the complete time within a cycling cell50. 
However, in response to DNA damage the DNA damage response (DDR) is initiated, holding the cell within 
G2 in order to repair the DNA or initiate apoptosis51. Experiments with DNA damage inducing treatments 
have shown that DDR arrest is associated with the rapid inactivation of CDC252,53. The DDR is initiated 
and sensed by the ATM and ATR kinases which activate the checkpoint kinases CHK1 and CHK254. 
CHK1/2 primarily mediate the G2/M arrest through the phosphorylation and inactivation of the phosphatase 
  
 
12 
 
 
CDC2555. Once CDC25 is phosphorylated by either CHK1 or CHK2 it is able to bind to the 14-3-3 family 
of proteins which then functions to translocate CDC25 out of the nucleus and into the cytoplasm55,56,57. 
Without CDC25 activity in the nucleus, CDC2 has no means to overcome the inhibitory phosphorylation’s 
on the tyrosine 15 and threonine 14 residues.  
The DDR through the ATM and ATR kinases also serve to modulate the activity of the tumor 
suppressor protein p53 through the phosphorylation of serine 15 in response to environmental stresses such 
as ultra violet58 and ionizing radiation52. The tumor suppressing protein and transcription factor p53 is 
primarily known for its roles in apoptosis, but it also has critical functions in cell cycle arrest and 
senescence59. p53 mediated cell cycle arrest can be initiated by the transcriptional increase of p21 which 
induces arrest through interactions with PCNA and multiple cyclin CDK complexes60,61. In a G2 arrest p21 
can inhibit the activity of CAK, a critical enzyme responsible for the activating phosphorylation of CDC2 
on threonine 161 however, experiments have shown no interaction between CAK and Kip proteins (p21, 
p27, p16, p18) suggesting the inhibition of CAK phosphorylation by p21 relies on an interaction with the 
cyclin CDK complex that makes the phosphorylation site on the CDK inaccessible to CAK62. 
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Figure 4. G2/M phase signalling. Central to G2/M phase regulation is the Cyclin B/CDC2 complex. Once Cyclin 
B is stabilized into the nucleus it is able to form a complex with CDC2. The Cyclin B CDC2 complex requires a series of 
phosphorylations and dephosphorylations to reach its full active state. In its active state Cyclin B CDC2 phosphorylates 
target genes necessary for mitotic progression.33 
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1.4 Mitosis 
 
Exiting G2, cyclin B/CDK1 is able to phosphorylate target proteins leading the cell into the 5 stage 
process of mitosis63. The ultimate goal of mitosis is to divide two equal copies of the genome into two 
daughter cells. In prophase the DNA condenses. During prometaphase the nuclear envelope dissolves and 
mitotic spindles begin to form. Within metaphase chromosomes align preparing for their separation in 
anaphase. Lastly the DNA decondenses, the nuclear envelope is made again, and the cell undergoes 
cytokinesis.  
During prophase, DNA condensation is mediated by posttranslational modifications of Histones64. The 
molecular signalling events of DNA condensation is still unclear however Aurora B Kinase has been 
implicated in the phosphorylation of Histone H3 during mitosis65. Cyclin B-CDK1 plays multiple roles 
during mitosis including the hyper-phosphorylation of lamins which disassembles the nuclear envelope66. 
Shortly after G2 exit, newly duplicated centrosomes sperate to opposing poles. The migration of the 
centrosomes has been shown to be regulated by multiple kinases including cyclin B-cdk1 and Plk1 which 
both phosphorylate and activate the kinesin related motor protein Eg567. Once the centrosomes are 
positioned, microtubule nucleation begins to form the mitotic spindles necessary for chromosome 
separation. Microtubules extend in a charge dependent process towards the kinetochores which are 
responsible for the attachment of chromosomes to microtubules68. At the kinetochore the spindle assembly 
checkpoint (SAC), senses and regulates the proper chromosomal attachment to microtubules. The primary 
function of the SAC is to inhibit progression until the microtubules are correctly attached to the 
kinetochores69. Prior to mitotic spindle attachment the SAC inhibits mitotic progression through the 
generation of the mitotic checkpoint complex (MMC) which actively inhibits the anaphase promoting 
complex (APC/C). The stable attachment of microtubules to the kinetochore inactivates the MCC releasing 
the inhibition on the APC/C and thus propelling the cell into anaphase70. APC/C is further activated by 
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cyclin B/CDK1 phosphorylation71 which consequently causes the ubiquitination and degradation of both 
cyclin B and securin. The degradation of Cyclin B inactivates CDK1 while the degradation of securin frees 
the enzyme seperase which allows for the opening of the cohesin ring structures that bind together sister 
chromatids72. Combined together, this leads to mitotic exit by allowing the separation of sister chromatids 
in anaphase eventually leading to cytokinesis and the formation of two daughter cell. 
Seeing as cancer cells go through more mitotic divisions than normal cells, many chemotherapeutic 
drugs aim to target mitosis. All currently approved drugs that target mitosis act to inhibit the proper 
formation of microtubules73. With improper spindle formation the SAC sustains a prolonged arrest leading 
the cell to apoptosis74. Additional mechanisms of cell death from mitotic drug targets exist,  including 
mitotic catastrophe75  and treatment induced senescence76.  
1.5 Senescence   
 
Cellular Senescence is a stable and permanent cell cycle arrest. For most of history it was thought 
that cells were immortal and could divide indefinitely until Leonard Hayflick refuted this by demonstrating 
that normal cells had a finite amount of divisions before permanently arresting into a state termed 
senescence77. The ability to bypass cellular senescence is one of the first hurdles a cell has to overcome in 
tumorigenesis. Seeing as cancer is a disease of uncontrolled cell growth treatment induced senescence 
through DNA damage, oxidative stress, and or oncogene activation is a promising avenue of cancer 
intervention especially so for apoptotic deficient tumors78.  
One of the distinguishing factors between senescence and quiescent cells is their ability to resume 
proliferation. While senescent cells are metabolically active, they do not respond to mitogenic signals like 
their quiescent counter parts. It has also been shown that senescent cells are much more resistant to 
apoptosis. Bio-markers of cellular senescence include chronically elevated p16 and p21 as well as 
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senescence associated beta-galactosidase activity. Morphologically, senescent cells present themselves as 
enlarged and flattened, additionally, senescent cells do not resume replication in response to passaging or 
to the exposure of growth factors. In essence, senescent cells remain viable and metabolically active yet 
lack any replicative ability79. On the molecular level the senescence programming is still very much an area 
of ongoing study. In response to DNA damage there is an initial rise in p53 and p21 levels which typically 
declines over a time course of days. p16, an inhibitor of multiple CDKs, has also been shown to steadily 
increase. These elevations have been linked to both the DNA damage response (DDR) and ARF pathways80. 
Another characteristic of senescence is the senescence associated secretory phenotype (SASP). SASP is a 
proinflammatory response of senescence. Senescent cells have been shown to release cytokines as well as 
matrix metalloproteinases (MMP) which is speculated to have a negative effect on malignancy and the 
tumor microenvironment. Current data suggests the material required for SASP is fed through the process 
of autophagy81. 
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3.0 Autophagy 
Our understanding of the complete autophagy pathway is still infantile and evolving however it has 
been implicated in a multitude of roles in a diversity of organisms. 2013 marked the 50th anniversary of 
Christian de Duve’s coining of the term “autophagy”4. Considered the father of autophagy, Christian de 
Duve carried out seminal studies leading to the discovery of the lysosome, a critical organelle responsible 
for the degradation of intracellular proteins. A few years later Clark and Novikoff independently observed 
irregular shaped vacuoles which carried cytosolic organelles including ER, mitochondria and ribosomes83. 
Arstila and Trumps observed that these double membrane vesicles lacked hydrolytic enzymes and termed 
them autophagosomes (AP)84. Sometime later the landmark discovery of a critical set of autophagy genes 
(ATG) in yeast by the Ohsumi lab earned Yoshinori Ohsumi the 2016 Nobel prize in physiology and 
medicine85. These discoveries, among others, laid the foundations of a new field and generated interest 
within autophagy research. The rapid rise of autophagy research is also highly attributed to its associations 
in disease states such as alzheimer’s and cancer. As such, autophagy provides promising new avenues in 
our understanding of health and disease. 
By definition macro autophagy is a catabolic process where cytoplasmic contents are packaged into 
autophagosomes (AP) and delivered to lysosomes for degradation and recycling. Autophagy flux 
encompasses the entire autophagy process and can be separated into five primary stages: induction, 
nucleation, elongations/closure, degradation and recycling (Fig. 5). Compared to the vast body of literature 
this review will only superficially focus on proteins involved in macro autophagy however, it is worth 
noting that many specific subcategories of autophagy have emerged including mitophagy, aggrephagy, 
lipophagy, and proteaphagy to name a few86. 
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Figure 5. Overview of 
Autophagy Flux. Various 
stimuli regulate autophagy. 
AMPK and AKT are canonical 
inducers and inhibitors. 
Autophagy induction funnels 
down to the activation of the ULK 
complex. Critical to vesicle 
nucleation is the induction of 
Beclin-1 by ULK1. Membrane 
formation requires the stepwise 
input of multiple proteins 
primarily found at a specific site on 
the ER termed the omegasome. 
The lipidation of LC3 to LC3-PE 
is required for membrane 
formation and maturation of the 
double membrane vesical termed 
the autophagosome. Cargo 
receptors such as p62 bind and 
tether cargo to the inner membrane 
of the autophagosome. Once 
formed the autophagosome fuses 
with the lysosome creating an 
autolysosome. The inner contents 
of the Autolysosome are degraded 
by pH dependent hydrolytic 
enzymes. The contents are 
recycled back into the cytoplasm 
by specific catabolite transporters. 
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3.1 Induction 
 
In response to a wide array of intra and extra-cellular stimuli, the induction of autophagy funnels down 
to the activation of the ULK complex (unc-51 like autophagy activating kinase 1). Upstream of the ULK 
complex are two canonical regulators of autophagy induction in mTORC1 and AMPK. These two proteins 
control autophagy depending, in part, on the energy status of the cell. AMPK responds to increases in the 
AMP:ATP ratio by both inhibiting mTORC187 and activating the ULK complex88. Conversely, under 
nutrient rich conditions the PI3K pathway phosphorylates AKT which then inhibits the TSC complex and 
consequently releases its inhibition of Rheb, a potent activator of mTORC1 typically localized at the 
lysosome89. Active mTORC1 is able to inhibit the lysosome90 as well as the induction of autophagy through 
phosphorylation of ULK1 on S757 and ATG13 on S25891.  
The active ULK1 complex consists of ULK1 and ULK2 combined with the scaffolding protein FIP200 
(FAK family kinase interacting protein) and subunits ATG101 and ATG13. When active, the ULK complex 
is responsible for phosphorylating an increasing list of proteins91. ULK1 has been repeatedly shown to 
facilitate the induction of autophagy through an activation of Beclin-192,93, a critical protein involved in the 
nucleation of the autophagosome94. 
 Multiple intracellular and extracellular signals can alter autophagy induction. In addition to metabolic 
stresses, calcium can modulate autophagy induction through CAMKII activation and phosphorylation of 
AMPK95. The DNA damage response and p53 induction has been shown to both initiate and inhibit 
autophagy96. Furthermore, anti and pro-apoptotic proteins Bcl-2 and BH3-only proteins can inhibit and 
induce autophagy, respectively97,98. All together a complex array of pathways including metabolism, cell 
death, and cell cycle as well as multiple stressors such as hypoxia, chemotherapy, ROS, infection, and much 
more converge onto autophagy induction99. This complexity suggests autophagy plays a central role in 
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many cellular mechanisms. The complexity also creates a challenge in measuring and understanding its 
role in specific cellular responses.  
3.2 Vesicle Nucleation 
 
Beclin-1 is a central factor of the class III phosphatidylinositol 3-kinase complex (PI3KC3-C1). This 
complex is critical to the nucleation of the phagophore, a precursor to the autophagosome94. PI3KC3-C1 
and the nucleation of the phagophore in mammalian cells is localized at an ER subdomain termed the 
omegasome. The omegasome is unique as it is concentrated with phosphatidylinositol 3-phosphates 
(PI(3)P) which are required for phagophore elongation100.  
Our understanding of the origins of autophagosome formation are still evolving, however new evidence 
has emerged that a physical interaction between organelles including the ER, mitochondria, PM and Golgi 
can facilitate membrane formation yet the primary source of autophagosome formation is still understood 
to come primarily from the ER membrane101.  
3.3 Elongation & Closure  
 
The formation of the autophagosome requires PI(3)P (concentrated at the omegasome), WIPI 1-4, 
GABARAPs and approximately 15 ATG (AuTophaGy) proteins interacting in a stepwise pattern102. 
Characteristic to autophagy is the eventual addition of a phosphatidyl ethanolamine group to LC3 (LC3-
II)103. This conversion of LC3 to LC3-II is popularly used as a biomarker for membrane formation104. As 
the phagophore elongates it engulfs cellular contents eventually reaching and fusing with itself forming the 
autophagosome.  
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Cargo receptors bind and anchor targeted proteins to LC3 or GABARAP tethering the cargo to the inner 
membrane of the autophagosome. p62 is one such protein which binds poly-ubiquitinated targets resulting 
in an aggregate of proteins termed aggresomes. Depending on the size of the ubiquitin chain these proteins 
are degraded through autophagy by means of the autolysosome or degraded in the proteasome105,106,107. p62 
is often measured as an indication of mature autophagosomes however it is important to be aware that p62 
has multiple functions including those within the ubiquitin proteasome system108.  
3.4 Lysosomal Fusion, Degradation & Recycling  
 
Lysosomal function is highly dynamic and critical to the complete flux of autophagy. Autolysosome 
maturation and lysosomal fusion are possibly the least understood events within autophagy. Transportation 
of the autophagosome to the lysosome has been shown to be microtubule depended. The motor protein 
Dynein is also implicated in the autophagosomes transport to lysosomes. With its outer membrane the 
autophagosome fuses with the lysosome. The SNARE family as well as HDAC6 are emerging as proteins 
required in autophagosome fusion with the lysosome109,110. The inner membrane along with the 
autophagosomes cargo is then degraded by hydrolytic enzymes in the now termed autolysosome. Around 
50 hydrolytic enzymes exist in the lysosome that allow it to fully degrade a diversity of substrates. These 
hydrolytic enzymes are dependent on the acidic pH of the lysosome which is maintained by ATP dependent 
proton pumps and over 20 more known membrane proteins at the lysosomal membrane111. Once degraded 
a diversity of catabolite exporters recycle the catabolic products back into the cytoplasm. 
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3.5 Autophagy and Cancer 
 
Autophagy has been shown to play a diversity of roles in both yeast and mammalian cells. As such 
autophagy in cancer has been proposed to have a diversity of promoting and antagonizing roles in 
tumorigenesis112. On a physiological level, tumors are more exposed to autophagic stimuli such as nutrient 
deprivation and hypoxia yet on a molecular level autophagy related genes and proteins can also be lost or 
suppressed113. Furthermore, the roles of autophagy within cancer in regard to cell metabolism, survival and 
death are deeply context and cell dependent. With this in mind the current literature indicates that tumors 
routinely utilize autophagy, in some form, to promote cell survival114–119. One study of interest investigated 
the differing dependencies on autophagy for proliferation by comparing both cancerous and non-cancerous 
breast cells in response to shRNAs for critical autophagy signalling proteins. Interestingly, all cancerous 
cell types studied showed reduced clonogenic capacity120. Furthermore, degrees of sensitivity to autophagy 
inhibition on proliferative capacity were seen across cell types.    
Patients who develop resistance to chemical therapy have been shown to have increased biomarkers for 
autophagy121. Additionally, clinical research has also supported the idea that inhibiting autophagy can lead 
to better patient outcomes117,122,123. Taken together the major focus of targeting autophagy in cancer is to 
inhibit rather than induce120. The antimalaria medicines Chloroquine (CQ) and Hydroxychloroquine (HCQ) 
are currently the only drugs approved to inhibit autophagy in humans. Full autophagy flux requires 
degradation by the lysosome. CQ accumulates specifically in the lysosome where it inhibits hydrolytic 
enzymes by raising pH. Early clinical trials combining CQ with radiation and chemotherapy on 
glioblastoma patients tripled the median survival122. Interestingly median survival times were also 
significantly improved when combining CQ with radiation alone124,125. The MTD of CQ for humans is 
unknown and an important area of future study. Additionally, better biomarkers of autophagy inhibition in 
human subjects are needed as the effectiveness of CQ and HCQ dosage on autophagy inhibition can be 
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highly variable from patient to patient. Lastly, it is important to note that although autophagy inhibition is 
the current focus, autophagy pathways are highly complex and context dependent. The scale of evidence 
weighs towards autophagy inhibition however arguments exist for and against. In contrast to above, the 
role of autophagy in regulating immune responses within tumors suggests the inhibition of autophagy may 
promote tumorigenesis126,126. A deeper understanding of the biological processes of autophagy regulation, 
as well as its context dependent roles in cancer are required to progress and safely target autophagy in 
cancer.  
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4.0 Programmed Cell Death  
 
Homeostasis requires both controlled cell division and death. Cell death works to maintain homeostasis 
by removing unnecessary or harmful cells. By the 1960s, through the work of developmental biologists, 
morphological characteristics of cell death were established. Shortly then after the scientific community 
began forming the hypothesis that cell death was a programmed and regulated event127,128.  
Based on morphological criteria there are three main categories of cell death. Apoptotic cell death (Type 
I), Autophagic cell death (type II), and necrotic/cytoplasmic cell death (Type III)129. It is important to note 
here that although categorization is convenient it does not always reflect the reality of the cell. Cell death 
is the end result of multiple contributing factors. In other words, the categorization of cell death pathways 
does not exist independently in a dyeing cell. The integration of cell signalling pathways and cell fate 
decisions is still mostly unclear yet understood to be context dependent. With this in mind, the following 
review will cover only the fundamental aspects of cell death.  
Although cancer displays a wide spectrum of heterogeneity many develop protein expression patterns 
designed to resist programmed cell death and promote cell survival88,130,131. p53 is a transcription factor 
critical to the cell’s response to DNA damage, repair and pro-apoptotic signalling. However, p53 function 
is lost in greater than 50% of cancers132. The upregulation of the PI3K/AKT pathway is another common 
theme in cancer and is responsible for numerous growth and survival functions. This commonly seen 
upregulation of cell survival pathways and downregulation in pro-apoptotic factors allows cancers to not 
only proliferate more rapidly but resist death as well. 
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4.1 Apoptosis  
 
Australian pathologist John Kerr with the aid of A.R Currie and Andrew Wyllie coined the term 
apoptosis after making the observation that various tissues displayed dying cells with similar morphological 
characteristics127. The consensus of apoptotic morphology would eventually be characterized as cell 
shrinkage, detachment, and membrane blebbing. Pyknosis, the condensation of chromatin would also 
become known to be characteristic of apoptotic cell death133. The genetic revolution brought fresh insight 
into our understanding that apoptosis and cell death was indeed a controlled and highly regulated event. 
Studies by Horvitz et al. on worms lead to the discovery of genes controlling cell death134. By 1993, the 
landmark discovery of the cysteine-aspartic proteases (CASPase), conserved from worms to mammals,135 
launches apoptosis from the dirt and into the vast field of research seen today128.  
In humans the Caspases are a family of 12 cysteine proteases involved in functions that are 
fundamental to the execution of apoptosis (Fig. 6)136. Apoptotic caspases can be organized into initiator and 
executioner caspases. Downstream of apoptotic signalling events initiator caspases are activated through 
proximity induced dimerization and subsequent self-cleavage. Once dimerized a cascade of activating 
caspase cleavages ultimately leads to the activation of the executioner caspases which results in the cleavage 
of a larger set of cellular proteins. The wide range effects of caspase cleavage which include DNA 
fragmentation, chromatin condensation and nuclear and cytoskeletal degradation all occur within a span of 
30-120 minutes137. In modern times the events leading to the execution phase of apoptosis, the initiation 
phase, is separated into the intrinsic and extrinsic pathways. The intrinsic pathway signals apoptosis through 
means of the mitochondria while the extrinsic pathway relies on the appropriately named death receptors 
found at the plasma membrane129.  
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Figure 6. Pathways in Apoptosis. Apoptotic pathways funnel down to the activation of initiator caspases which further activate 
executioner caspases responsible for the programmed death of the cell. Caspase activation can be initiated by both intrinsic and 
extrinsic mechanisms.  Intrinsic activation requires suppression of anti-apoptotic factors in response to cellular stressors such as 
DNA damage and nutrient deprivation.  Once anti-apoptotic factors are sufficiently supressed MTPs open releasing multiple pro-
apoptotic effectors which commit the cell to caspase dependent and or independent apoptosis. The extrinsic pathway is activated 
in response to ligands binding to death receptors at the PM. Once bound the intracellular end of the death receptor facilitates the 
activation of the initiator caspases. The extrinsic pathway integrates with the intrinsic pathway by initiator caspase mediated 
opening of the MTP through Bid and tBid129,136-142.   
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4.1.1 Intrinsic Pathway 
 
The intrinsic pathway of apoptosis is centralized at the mitochondria and regulates apoptosis 
primarily in response to intracellular cues such as ROS and DNA damage. The inter-membrane space stores 
proteins such as cytochrome C (Cyt C) and AIF which are individually capable of carrying out apoptosis133. 
These mitochondrial factors are always ready for liberation however constitutively active anti-apoptotic 
factors such as the BCL-2 family of proteins serve to inhibit this release138. Upon stress pro-apoptotic factors 
are transcribed and activated. In response to DNA damage the transcription p53 induces the transcription 
of pro-apoptotic factors BAD, NOXA and PUMA139. These pro-apoptotic factors actively suppress the anti-
apoptotic factors facilitating the opening of the Mitochondrial transition pores (MTPs). The opening of the 
MTP allows the release of apoptotic effectors including AIF, Endonuclease G, CAD, and Cytochrome C. 
The release Cytochrome C is considered an irreversible step in apoptotic programing and marks the cells 
full commitment to cell death. Upon release Cytochrome C interacts with APAF-1 and pro-caspase 9 
forming the apoptosome and subsequent activation of executioner caspases136,140.  
4.1.2 Extrinsic Pathway 
 
The extrinsic pathway initiates apoptosis by means of extracellular cues. Death receptors at the 
plasma membrane bind ligands such as TNF-A, FasL, and DR5129. On the intracellular side transmembrane 
receptors play enzymatic roles facilitating the localization, dimerization, and catalytic cleavage of initiator 
caspases which leads to executioner caspase activation and apoptotic commitment141. The extrinsic pathway 
overlaps with the intrinsic pathway through the activation of Bid and tBid by the TNF-A R1/Fas receptor. 
Upon activation tBid translocates to the outer mitochondrial membrane where it oligomerizes BAX or BAK 
causing the release of Cytochrome C142. 
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4.2 Necrosis & Necroptosis  
 
Cell death is mostly actively programmed and controlled within cells to respond accordingly to the 
surrounding environment. Programmed cell death is carried out in a controlled manner with limited affect 
to the surrounding area. In contrast non-programmed cell death can occur in the event of irreparable damage 
to the plasma membrane. Unlike Apoptosis, where the cell dies in an immuno-silent manner, necrosis 
requires the inflammatory response in order to clear the cellular debris143. As such, Necrotic cell death is 
implicated in many pathological conditions144. Although Necrosis is known as a passive, energy 
independent form of cell death, there has been increasing evidence of forms of necrosis with defined 
molecular events143. Active necrosis entails an extensive list of emerging pathways relating to mitochondrial 
function, lysosomal function, NADPH-Oxidase, PARP-1, proptosis, ferroptosis and others. Active necrotic 
pathways are still currently being elucidated and as such overlapping mechanisms between cell death 
pathways still require research144. That said, necroptosis is likely the most well studied form of active 
necrosis. Initially used as a term to describe any active form of necrosis recommendations define 
necroptosis as any necrotic cell death that is reliant on the protein kinase RIPK3146. Advances in biomarkers 
and specific necrotic inhibitors such as nec-1s give promise to both research and future clinical application.  
In cancer, the necrotic discharge of cellular contents releases intracellular signals termed damage-
associated molecular patterns (DAMPs) which promotes tumor progression by means of 
immunosuppression, angiogenesis, proliferation, and inflammation147. All together necrosis is implicated 
in a tissue level resistance to anti-cancer drugs148. As necrotic signalling promotes tumor progression the 
inhibition of necrotic secreted signals serves as an area of interest in improving the efficacy of current and 
future cancer therapies.  
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4.3 Autophagy mediated cell death 
 
Autophagic cell death is a somewhat poorly understood and controversial topic. The controversy 
stems from both a lack of standard in measuring autophagy flux and distinguishing cell death by versus 
with autophagy. Autophagy is widely known to be a pro-survival mechanism however, there are instances 
where autophagy plays direct roles in mediating cell death149. Cell death by autophagy should be reversible 
by two or more knockdowns and or chemical inhibitors of core autophagy machinery. Furthermore, 
inhibitors of other cell death pathways such as apoptosis and necroptosis should not alter the response. 
Autosis, studied and coined by Beth Levine et. al is one such form of autophagy mediated cell death that 
fits these criteria. Induced by Tat-Beclin 1 transfection and inhibited by antagonists of the Na+/K+ ATPase, 
Autosis is characterized by increased autophagosomes, nuclear convolution and focal swelling of the 
perinuclear space150. Although Autosis is a novel insight into autophagy mediated cell death, its place as a 
physiological phenomenon is yet to be established. 
Autophagy has also been shown to play roles in the scaffolding of cell death machinery. Deletion of 
the tumor suppressor Map3k7 was shown to cause a sensitization of cells to necroptotic cell death mediated 
by p62 recruitment of RIPK1151. The recruitment of RIPK1 increased the interaction of the complementary 
components of the necroptosome (RIPK3, MLKI). Interestingly, knockdown of p62 led to the activation of 
apoptosis though the interaction of free RIPK1 with caspase 8 and FADD. Furthermore, the lysosomal 
inhibitor chloroquine, a compound known to cause the accumulation of autophagosomes, amplified the 
necroptotic response. The added autophagosomes theoretically provides more opportunity for the 
scaffolding of the necroptosome. Ultimately, the scaffolding functions of autophagy are a good example of 
how cell death pathways are becoming more established as a continuum of mechanisms rather than separate 
independent categories.  
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5.0 Electrical Pulse Stimulation (EPS)  
 
Before electricity rapidly revolutionized society it slowly evolved as an integral force within our 
biology. Electricity was first studied by anatomists and physiologists within organisms including electric 
eels and torpedo fish. Throughout the 17th and 18th century physicists learned how to control the flow of 
electrons much like the torpedo fish of the past. In the early years it was found that electricity had many 
effects on the human body152. Notably, the initiation of muscular contractions, increases in heart rate, and 
if extreme enough death. From the 19th century to present it is clear that technology and our understanding 
of electricity has revolutionized our society. The medical field harnesses electricity in almost all equipment 
from pagers to electro-cardiograms, however, there has not been many well researched applications of 
electricity as a direct therapeutic for diseased states such as cancer. 
The first documented use of EPS within cell culture was published in 1976 by Shainberg & Burstein 
who used platinum electrodes to study the effects of EPS on acetylcholine receptor regulation in chick 
muscle cells153. Following this pioneering study, the utilization of EPS has been predominantly used to 
study the physiological, cellular, and molecular responses of nerves and innervated tissues such as 
myotubes and myoblasts154. Prior to this paper EPS has not been studied as a breast cancer intervention.   
When it comes to the usage of EPS there is an infinite amount of combinations of parameters including 
but not limited to: time, voltage, frequency, pulse width, and polarity. The large spectrum of possible 
parameters in the application of EPS creates a layer of difficulty when comparing results across studies 
however, the diversity of unique modes of EPS also creates exciting opportunities for its research and 
application.  
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Figure 7. Historical Context of the EPS of Breast Cancer. In-vitro EPS has historically been used to study the response of 
excitable cells in cell culture. It has been used extensively on myotubes as a model of in-vitro exercise. More recently in cell 
culture EPS has been used to study the differentiation of non-excitable myoblasts. It was discovered myoblasts also respond to 
EPS, inducing cell cycle exit at G1 and myotube differentiation. Further studies into rhabdomyosarcoma (RMS), a childhood 
muscle cancer, showed a similar result however through a differing mechanism. RMS cells arrested in G2 and showed drastic 
increases in the autophagy associated membrane protein LC3-II. These results led us into our current study of EPS on MCF7s. 
Darker boxes indicate work done in our lab. 
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5.1 EPS of Myotubes 
 
The physiological pathway leading to skeletal muscle contraction is a well understood 
phenomenon. Action potentials from nervous input or an applied electrical input are propagated through 
sodium channels across the T tubule. The T tubules invaginate into the muscle and ultimately cause an 
interaction between voltage sensitive Dihydropyridine and Ryanodine receptors. This interaction allows the 
release of calcium from the Sarcoplasmic Reticulum (SR). The SR is very similar to an ER however it is 
exclusive to muscle and stores a far larger amount of calcium than the ER. Calcium released from the SR 
is able to bind to troponin and facilitate the cross-bridge cycling of actin and myosin which creates the 
muscle contraction. The action potential within the T tubule is terminated via voltage sensitive calcium 
channels. Calcium is sequestered back into the SR through ATP dependent SERCA receptors155. 
Studies of in vivo exercise and in-vitro EPS of myotubes have shown many similarities across a 
multitude of studies. Both interventions increase the mRNA expression of PGC1a, PDK4, MYH7156, as 
well as multiple myokines (IL-6, IL-8, NAMPT, ANGPTL4)157. Both increase Ca+2 transients158,159 which 
has been linked to increases in the activity of AMPK160, ERK1/2, and JNK161. During short term bouts of 
EPS, the phosphorylation of AKT has been shown to increase as well162. In-vivo and in-vitro studies have 
also shown alterations in oxidative phosphorylation, MHC I, and NF-kB. Metabolic effects of EPS on 
myotubes also include increases in GLUT4 translocation, glucose uptake, mitochondrial biogenesis, 
myokine secretion, ROS buildup, NO and decreases in glycogen163.  
 
 
 
  
 
33 
 
 
5.2 EPS of Myoblasts 
 
Skeletal muscle begins in an intermediary undifferentiated state as a myoblast. Myoblasts lack the 
calcium handling capabilities of myotubes yet are able to proliferate until differentiation into myotubes, a 
process that requires cell cycle exit. The lack of calcium handling organelles, such as the sarcoplasmic 
reticulum, and ability of proliferation, makes myoblasts a good intermediary model for predicting the 
potential responses of other non-excitable cell types. In our lab EPS (4h/day, 6 days, 5Hz 10V) was applied 
to C2C12 myoblasts164. Western blot analysis revealed that EPS induced a 6-fold increase in p27 with a 
correlated decrease in Cyclin E levels. Additionally, Cyclin E was also shown to have increased interaction 
with p27. All together this indicates a protein expression pattern typically seen in a G1/S arrest. It was also 
shown that in response to EPS the phosphorylation of AMPK on T172 elevated. This phosphorylation is 
important for the stabilization of p27 levels necessary for the inhibition of cyclin E. By inhibiting Cyclin 
E, the cell is arrested at the G1/S transition. The study concluded that in response to EPS, C2C12 myoblasts 
showed a protein expression pattern indicative of a G1/S arrest.  
Our lab also previously studied the early response of proliferating myoblasts to one bout of 
electrical stimulation165. In this study EPS was applied to C2C12 myoblasts for 4 hours/day (10V, 5Hz) 
with a 20-hour rest period. In agreement with previous studies EPS induced an increase in AKT and AMPK 
phosphorylation. However, total p27 protein levels were unaffected. EPS did however induce the nuclear 
translocation of p27. Localization of p27 to the nucleus is critical for p27 to fulfill its roles in cell cycle 
arrest34,38. Additionally, LC3-II levels were immediately upregulated and diminished 16 hours following 
EPS. Altogether this study concluded EPS of C2C12 myoblasts induced cell cycle arrest, potentially 
through AKT and AMPK signaling and altered the autophagic status of the cell. 
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5.3 EPS of Rhabdomyosarcoma 
 
Rhabdomyosarcoma (RMS) is a form of malignant cancer that originates from striated muscle. It 
is the most common soft tissue sarcoma within childhood cancers. RMS cells contain muscle like properties 
however they are unable to terminally differentiate into myotubes, thus this cell type holds an interposition 
between non-excitable myoblasts and other non-excitable cancer cell types. In our lab, we previously 
applied our knowledge of muscle biology and EPS to RMS cells166. RMS cells were subjected 4 hours of 
EPS/Day (5Hz, 5V) from anywhere between 1 and 5 days. RMS cells showed proliferative arrest, cell death 
and morphological changes throughout the five-day time course. Contrary to previous work on myoblasts 
the reduction in cell number was primarily attributed to a G2/M arrest confirmed by propidium iodine 
staining and subsequent FACS analyses. By the 4th day Western blot analysis also revealed an increased 
conversion of LC3-I to LC3-II. This indicated the involvement of autophagic pathways in response to the 
stress of EPS. Interestingly AKT on threonine 308, a critical cell survival response and inhibitor of 
autophagy induction, was induced while pAMPK at threonine 172, a canonical inducer of autophagy 
induction was shown to decrease. Altogether RMS cells responded in similar fashion to myoblasts however, 
the mechanism of action differed. The arrested state of cells in response to EPS sparked interest into the 
ability of other non-excitable cancer cell types. Furthermore, as autophagy is a relatively new and evolving 
field the intersection of autophagic activity, cell cycle arrest and cell death serve as an emerging area of 
interest. 
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6.0 Hypotheses & Research Objectives 
 
This research project is focused on in-vitro EPS of MCF7 breast cancer cells. The ultimate goal is 
to characterize and investigate the response of MCF7s to EPS. The following objectives and 
hypotheses are based off the prior work detailed above. In accordance with the response of EPS to 
RMS cells EPS will attenuate cell growth eliciting a G2/M cell cycle arrest, induce cell death and 
upregulate autophagy associated proteins. Since non-excitable myoblasts have previously been shown 
to have calcium dependent EPS responses we also hypothesize that chelating calcium will attenuate 
the EPS response in MCF7s. In line with these hypotheses my objectives are to quantify cell 
proliferation and viability, investigate potential mechanisms of cell cycle arrest, measure markers of 
autophagy, and compare results with the presence and absence of the calcium chelator BAPTA-AM. 
Additionally I aim to investigate whether a time and or dose (voltage) dependent response to EPS 
within MCF7s exists. 
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7.1 Abstract  
 
Electrical Pulse Stimulation (EPS) has been predominantly used to study the physiological, cellular, 
and molecular responses of excitable cells such as nerves and skeletal muscle. However, it has been recently 
shown that non-excitable cells, including myoblasts and rhabdomyosarcoma cells, slow proliferation in 
response to EPS.  Thus, we hypothesized that EPS would also elicit favorable growth inhibitory responses 
in breast cancer (MCF7) cells.  MCF7 cells were subjected to EPS (5 Hz, 6-10 V, 4 hrs/day) for up to 2 
days in cell culture and changes in morphology, protein expression and proliferation were evaluated. EPS 
resulted in dramatic reductions in cell numbers, that were not a result of necrosis, and stark morphological 
changes associated with mitotic catastrophe and cellular senescence. Prior to cellular senescence EPS 
arrested cells in G2/M while concurrently increasing the expression of the cell cycle inhibitor p21, in what 
may be a p53 independent manner. In addition to these large and rapid reductions in cell numbers, EPS 
radically increased the protein levels of the autophagy markers LC3(I/II) and p62 in a calcium-dependent 
fashion, while also potentially causing an inhibition in the late stages of autophagy in a calcium-independent 
manner. Furthermore, it appears that p62 elevations following EPS play a role independent of the 
autophagosome that may potentially serve as a mechanism of cell survival and proteostasis. 6-fold increases 
in the activation of the AKT pathway also suggest a strong cell survival response and a hypertrophic 
phenotype that may contribute to cellular senescence through mTORC1 activation. Taken together these 
results provide a framework for the development of EPS as a potential novel localized therapy to breast and 
other cancer cell types.  
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7.2 Introduction  
Cancer is a disease of perpetual uncontrolled and unwanted cell division. If left untreated, from a 
single cell this unwanted cell division can accelerate, aggregate, and spread thus, expanding its territory 
and further disrupting health and homeostasis2. The control of cell division is comprised of a complex and 
tightly regulated series of checks and balances known as the cell cycle; a process fundamental to preventing 
aberrant cell growth24.  In cancer, when proliferative control has been lost, the ability to force cell cycle 
arrest can represent a major step in halting disease progression27. Cell division depends on a balance 
between cell cycle accelerators (i.e. cyclins/CDKs) and cell cycle inhibitors (i.e. p27, p21)32,38,42,167. In order 
to reign in proliferation, a shift in the balance between these cell cycle regulatory proteins that favors 
quiescence is necessary. There are multiple avenues to achieve cell cycle withdrawal, including decreased 
cyclin/CDK activity and/or increased activity of cell cycle inhibitory pathways, all of which can be invoked 
by both internal and external stimuli34,53.  
Originally autophagy was primarily identified as a metabolic process yet more recently it has 
been implicated in the regulation of an expanding range of functions86. Autophagy is a catabolic process 
where cytoplasmic contents are packaged into double membraned vesicles, termed autophagosomes, 
which are ultimately delivered to lysosomes for the enzymatic degradation and recycling of their 
contents82. Autophagy has been implicated in the regulation of a wide range of functions including 
proliferation and cell death96,120,150,151. Furthermore, autophagy induction has been elucidated as an 
important mechanism for adaptive chemotherapy resistance in tumor cells168. A common marker of 
autophagic activity is the formation of the double membraned mature autophagosome which is dependent, 
in part, on the microtubule-associated protein light chain 3 (LC3)169. During autophagosome maturation 
LC3-I is converted to LC3-II by the addition of a phosphatidyl ethanolamine group103. This conversion is 
often used as a general indication of the autophagic activity within the cell. However, alterations in LC3 
protein content alone has limitations as it does not account for autophagic flux which encompasses the 
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entire process of autophagy from induction to protein degradation. Since variations in LC3-II content can 
be attributed to alterations across and within multiple stages of autophagy, it is important to consider the 
entire process of autophagy flux including both synthesis and degradation events when contextualizing 
autophagy markers such as LC3-II. Selective autophagy is a subdivision of autophagy which requires 
specific cargo receptor proteins such as p62, a commonly used autophagy marker that is typically 
localized within the autophagosome and destined for degradation following lysosomal fusion170. p62 
reductions are used as an indication of increased degradation within the autolysosome due to an increased 
flux, while elevations in p62 typically imply an inhibition of degradation within the late stages of 
autophagy which would cause an accumulation of autophagosomes. It is also important to consider 
changes of LC3-I and p62 protein content can be indicative of events outside of the autophagosome 
including the p62 dependent accumulation of LC3 in protein aggregates171–173, a process that can be 
implicated in autophagy, the ubiquitin proteasome pathway and cell survival105.  
Electrical Pulse Stimulation (EPS) has been used for decades as a means to elicit cellular 
adaptations in vivo by altering membrane polarity. Shainberg & Burstein first used EPS in cell culture in 
1976 as a method for studying the regulation of electrical activation of chick muscle cells153. EPS of 
differentiated myotubes in cell culture elicits similar responses to those seen in skeletal muscle stimulated 
by the motor nerve in vivo, showing its utility as a suitable functional model156. Thus, using EPS in cell 
culture has provided a reliable and representative means to control and isolate the specific molecular and 
cellular events responsible for the adaptations to muscle contraction. Recently, it has been shown that the 
EPS of non-excitable myoblasts induces cell cycle arrest and subsequent differentiation into myotubes164,165. 
The molecular signaling events and reductions in the proliferative capacity of myoblasts necessary for 
terminal differentiation suggested that EPS could represent a way to induce novel phenotypic alterations in 
other non-excitable cell types, including cancer cells. Rhabdomyosarcoma (RMS) is an aggressive 
childhood cancer whose cells demonstrate muscle gene expression profiles similar to those seen in 
myoblasts/satellite cells174. When subjected to EPS, RMS cells arrested in G2/M and demonstrated an 
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increase in the autophagy markers LC3-I and LC3-II166. Since EPS was able to elicit these potential anti-
proliferative effects in non-excitable RMS cells, the possibility existed that EPS could elicit similar 
phenotypic alterations in other non-excitable cancerous cell lines.  
In the current study MCF7 breast cancer cells were subjected to EPS at multiple intensities in cell 
culture. We report herein that EPS sets in motion a program of proliferative failure, indicative of 
senescence, that arrests the cell in G2/M in what may be a p53 independent manner. EPS also markedly 
increases the autophagy markers LC3 and p62 in a mechanism that suggests an increased induction of 
autophagy in a calcium dependent fashion, while concomitantly inhibiting the late stages of autophagy 
through a calcium independent mechanism. Thus, given that the upregulation of autophagy has been 
identified as a critical adaptation in tumors that leads to chemotherapy resistance119, inhibiting the late 
stages of autophagy with EPS might be a novel method in sensitizing tumor cells to chemotherapy while 
also facilitating the failure of tumor growth. Taken together, these results provide a framework for the 
application of EPS to other cancer cell types with the ultimate goal of developing a novel localized cancer 
therapy. 
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7.3 Materials and Methods  
 
Cell Culture MCF7 breast cancer cells were incubated at 37°C and 5% CO2 in Minimum Essential Medium 
Eagle, Alpha Modification (AMEM; Sigma Mississauga, ON), supplemented with 5% FBS (Wisent, 
Montreal, QC) 3% antibiotic antimycotic, 1% sodium pyruvate, 1% Non-essential amino acids and 10µg/ml 
of human insulin (Sigma). For LDH experiments phenol free MEM (Gibco Fisher Scientific, Mississauga, 
ON) was used as described for AMEM above with the exception of sodium pyruvate.   
Electrical Pulse Stimulation MCF7 cells were cultured in 6-well plates and stimulated using a lid which 
was modified with two parallel platinum wire electrodes extending into the media. A total volume of 5.5ml 
per well was used to ensure consistent delivery of EPS to the media. Cells were stimulated using a Harvard 
Apparatus Stimulator CS System (Harvard, MTL, QC). 6, 8 or 10 Volts applied at a frequency of 5 Hz with 
alternating polarity of current for 4 hours with a 20-hour rest period for either 1 or 2 days.  
Cell Collection Cells were harvested at various times and washed with cold Phosphate Buffered Saline 
(PBS, Wisent), scraped, and centrifuged (2320 x g at 4°C). The pellet was resuspended in TENT buffer 
(0.2% TENT – TRIS, EDTA, NaCl, 0.2% Triton x-100), and 1% phosphatase inhibitor (Phos-Stop, Roche 
Diagnostics, Montreal, QC). Cell were sonicated (20% Max) and centrifuged (16168 x g at 4°C). The 
resultant supernatant was removed and stored at -80°C for future analyses.   
Immunoblotting Protein concentrations of collected samples were determined using a Bradford assay and 
25µg of protein were separated using an SDS polyacrylamide gel electrophoresis (PAGE, 12% and 16% 
gels). Following electrophoresis proteins were transferred overnight (4°C, 40V) onto a PVDF membrane. 
Quality of transfer was confirmed using amido black staining and membranes were blocked for 2 hours in 
10% milk at room temperature. Membranes were probed overnight (4°C) with primary antibodies for: 
AMPK, pAMPKT172, AKT, pAKTT308 , LC3I/II, p53, Beclin-1, (Cell Signaling, Whitby, ON), p27 (BD 
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Biosciences, Mississauga, ON), p27T198 (R&D Systems, Minneapolis, MN), Cyclin E, p62, COXIV, b-actin 
(Abcam, Cambridge, MA), and p21 (Santa Cruz, Dallas, TX). Following incubation with primary 
antibodies, membranes were rinsed 3 times using a Tris-Buffer Saline with Tween-20 (0.05%) (TBST) and 
incubated with HRP-linked anti-rabbit and anti-mouse secondary antibodies (Cell Signaling, Whitby, ON) 
in 5% milk with shaking at room temperature for 1 hour. Membranes were subsequently washed 3 times in 
TBST at room temperature and protein levels were visualized using enhanced chemiluminescence 
substrates (Millipore, Whitby, ON) with a Kodak In Vivo FX Pro imager. Images were quantified using 
Carestream software (Marketlink Scientific, Burlington, ON). b-actin was used to control for protein 
loading.  
Assessment of cell Viability and Growth Inhibition Cell viability was quantified using a modified LDH 
assay175,176 to measure the activity of lactate dehydrogenase (LDH) released as an indication of cell death. 
Briefly, free floating LDH released from dead cells into the media is able to reduce NAD+ to NADH. Newly 
synthesized NADH facilitates the production of formazan which can be measured spectrophotometrically. 
The amount of formazan was measured using a microplate reader (BIOTEK, Vermont, MN; 490nm). 1ml 
of media was removed for the measurement of the released LDH (sampled media). LDH release values 
were compared to a condition of complete cell death which was elicited by exposing the well to a 10x Lysis 
Buffer (10% Triton X-100) for 30 minutes. Following the 30 minutes 1ml of this complete lysis media was 
collected as a representation of the total LDH derived from outside and inside of the cells. Media alone, 
absent of cells, was used to measure background LDH values. After subtraction of background, LDH 
release values (sampled media) were subtracted from maximum LDH release values (lysis media) and this 
value represented the amount of LDH within the adherent living cells. The LDH within living cells was 
measured for controls and EPS cells before as well as 4, 24, 28, 48 and 72 hours following the onset of 
EPS. Total live cell LDH measurements were expressed as a ratio between EPS and controls. This value 
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represents the percentage growth inhibition of the treatment condition. More details of calculations and 
methods used were published previously175,176. 
Cell cycle Analysis MCF7 cells were collected via tyrpsination, pelleted and washed twice in cold PBS. 
Following washing cells were fixed by the dropwise addition of ice cold 70% ethanol and stored at -20ºC. 
The cells were incubated overnight in staining solution (750μl of PBS, 200 μl of 50 μg/mL propidium iodide 
Bioshop, Burlington, ON) and 50 μl of 10 μg/mL RNase (Sigma Mississauga, ON)). DNA content was 
measured using an Attune NxT Flow cytometer (Fisher Scientific, Mississauga, ON) and cell cycle profiles 
were determined using FlowJo software (BD Biosciences, Mississauga, ON). 
Pharmacological treatments BAPTA-AM, a chelator of intracellular calcium ions, was used to assess the 
role of Ca2+ in the cell when responding to EPS. DMSO was used as a reliable control. BAPTA-AM was 
added to the media at concentrations ranging from 4 µM to 12 µM. Chloroquine (CQ), a lysosomotropic 
compound that is routinely used to investigate late stage autophagy flux, was added to media at 
concentrations ranging from 2.5 µM to 20 µM with DMSO used as a control. CQ accumulates in lysosomes 
where it raises the lysosomal pH thus inhibiting the pH dependent hydrolytic enzymes required for 
lysosomal degradation. LC3 and p62 levels were measured via western blotting to infer changes in 
autophagosome formation and degradation, respectively.  
Senescence Associated b-Galactosidase (SA-b-Gal) Staining Cellular Senescence was assessed using a 
SA-b-Gal staining kit (Cell Signaling, Pickering, ON). Cells were washed with PBS and fixed for 15 
minutes. Following fixation cells were washed again with PBS and subsequently placed in a dry 37°C 
incubator (0 % CO2) overnight. SA-b-Gal activity was indicated by blue staining and this was qualitatively 
assessed via brightfield microscopy (10x magnification). 
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Statistical Analyses Statistical analyses were done using GraphPad Prism 5 software. One and two-way 
ANOVAs followed up by a Tukey’s post-hoc test were used to determine differences between individual 
groups. Error bars are represented as ±SEM and statistical significance was determined when p≤0.05. 
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7.4 Results 
 
EPS results in growth inhibition and not necrosis EPS (2 d x 4 hrs/d) resulted in a noticeable reduction 
in the number of cells visible using light microscopy (Fig. 1A, panel 1 vs. 3). This phenomenon was even 
more evident 72 hours after the onset of the first bout of EPS (Fig. 1A, panel 2 vs. 4). Given that this EPS 
dependent decrease in cell number could be a result of decreased proliferation and/or increased cell death, 
we assessed cell viability and proliferation using a modified LDH assay9,175. LDH is released into the media 
from cells with cytoplasmic damage caused by necrotic cell death. The amount of LDH released into the 
media from cells exposed to EPS was measured and compared to LDH released into the media of non-
stimulated control cells. In addition to measuring LDH released into the media, total LDH was measured 
by lysing cells and collecting the resulting media. This total LDH value was used to calculate the percentage 
of LDH released for each condition and timepoint. Measurements were taken before and after both bouts 
of EPS (0, 4, 24, and 28 hrs) as well as 48 and 72 hours following the onset of EPS. LDH release from EPS 
cells was not increased 72 hours after the onset of EPS (Fig. 1B) and no change in the difference between 
EPS and non-stimulated controls over time were evident (Fig. 1C). While there was a statistical difference 
between EPS and non-stimulated control cells at 72 hrs, this difference is attributable to LDH released from 
control cells being less than the background values. These results suggest that EPS does not induce necrosis 
and that the vast majority of cells remained viable after EPS. By lysing the attached cells, measuring LDH 
activity and comparing this activity in EPS and non-stimulated cultures, an assessment of relative cell 
number was evaluated. Following cell lysis, total LDH activity was measured at all timepoints with the 0 
hour non-stimulated control values used as a reference point. Total LDH did not differ between the EPS 
and control cultures for the first 28 hours. After the 2nd bout of EPS (28 hrs) total LDH in non-stimulated 
controls progressively rose while EPS conditioned cells remained unchanged (Fig. 1D). By 48- and 72-
hours post onset, the total LDH activity of EPS conditioned cells was 54% and 83% lower than that of non-
stimulated controls (Fig. 1E). In agreement with light microscopy images (Fig. 1A), this differential in total 
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LDH activity is a strong indication and representation of the reduction in cell number and growth inhibition 
seen in response to EPS. Taken together these data indicate that EPS induces drastic and sustained decreases 
in proliferation.  
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Figure 1. EPS results in growth inhibition and not necrosis. (A) brightfield microscopy images (4x magnification) of control (panels 1,2) relative to 
EPS conditioned cells (8V) (panels 3, 4) taken 28 and 72 hours following the onset of EPS. (B) LDH release activity over 72 hours. Following 
background subtraction all LDH release values are calculated as the percentage of the total LDH activity. (C) LDH release activity represented as the 
percentage of necrotic cells. The percentage of necrosis in EPS conditioned cells was subtracted from the percentage of necrotic cells of parallel controls. 
(D) Total LDH activity over 72 hours. Total LDH activity attained from measuring LDH activity in cultured cells under a condition of complete cell 
lysis. (E) Represented as the relative inhibition of growth, the total LDH activity of controls was subtracted from respective total LDH values from EPS 
conditioned cells. For (B-E) all values are represented as the mean ± S.E.M.; * p≤0.05 (N = 4-6) 
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EPS induces cellular senescence LDH experiments indicated that EPS induced reductions in 
proliferative capacity. In order to assess whether the EPS dependent changes in proliferative capacity were 
transient or permanent, cells were stimulated (4hr/d, 2d, 10V) and re-plated with fresh media. Cell 
morphology and growth was monitored over both days of EPS exposure (Fig. 2A) as well as 4 days 
following re-plating (Fig. 2B). Immediately after the first bout of EPS the cells were morphologically 
identical to non-stimulated cells (Fig. 2A, 4 hrs) however, 24 and 48 hours following the onset of EPS 
distinct morphological differences emerged (Fig. 2A). Cells undergoing EPS had a noticeable population 
with a small and rounded appearance (Fig. 2A, Arrows). Differences were magnified over time with cells 
undergoing EPS attaining an enlarged flattened morphology (Fig. 2B). Furthermore, EPS cells also 
contained puncta both at the plasma membrane and clustering towards the nucleus (Fig. 2B, Arrows). 
During the 4-day period following re-plating, cells exposed to EPS showed no discernable increase in 
confluence while non-stimulated control cells reached 100% confluence and required re-plating every 48 
hours (Fig. 2B). Thus, EPS appeared to induce a permanent alteration in proliferative capacity. 
Additionally, the enlarged flattened morphology further suggested EPS may have induced cellular 
senescence. To assess whether EPS indeed activated a senescence program, cells were stained for 
senescence associated b-Galactosidase (SA-b-Gal) activity (Fig. 2C). SA-b-Gal staining showed a distinct 
increase in positive staining in the vast majority of EPS cells (Fig. 2C, panel 2) relative to the control cells 
(Fig. 2C, panel 1) demonstrating an increase in cellular senescence indicated by the appearance of distinct 
black nuclei (Fig. 2C, Arrows). 
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Figure 2. EPS induced 
morphology and senescence. 
(A) Brightfield microscopy 
images of control and EPS 
conditioned cells over 48 hours. 
Arrows indicating cell rounding. 
(B) Brightfield microscopy 
images of control (panels 1-2) 
and EPS conditioned cells 
(panels 3-4), 4 days following 
re-plating (6 days following the 
onset of EPS). Larger arrows 
indicating double nucleated 
cells, smaller arrows indicating 
puncta radiating from nucleus of 
enlarged flattened cells. (C) 
Brightfield microscopy images 
of SA-b-Gal stained control 
conditioned (panel 1) and EPS 
conditioned (panel 2) cells taken 
4 days following re-plating (6 
days following the onset of 
EPS). Arrows indicate examples 
of positive staining. 10x 
magnification for all images 
with exception to B panels 1 and 
3 (4x magnification). 
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EPS does not cause a G1 arrest but rather a G2 /M arrest Cellular senescence is classically associated 
with a G1 arrest177–180 therefore, we measured the effects of EPS on proteins known to control the G1-S 
transition. pAMPK T172 phosphorylation is commonly associated with a G1 arrest in response to 
metabolic stress181. Compared to controls pAMPKT172 protein levels were decreased by approximately 
53% with EPS. At the maximum intensity of EPS (10V) a time dependent relationship was evident, with a 
further reduction in pAMPKT172 in EPS cells from 56% to 30% between 1 and 2 days, respectively (Fig. 
3B). In contrast, pAKTT308 , a phosphorylation site known to drive cell growth and G1/S phase progression34, 
showed large elevations in protein levels, reaching values that were 370% higher in EPS cells compared to 
non-stimulated control cells (Fig. 3C). No differences in total AMPK or AKT were evident. EPS also had 
no effect on the protein levels of the CDK inhibitor p27 (Fig. 3D). Furthermore, cyclin E protein 
demonstrated decreases of up to 37% in protein levels compared to non-stimulated cells (Fig. 3E). Taken 
together, the effects of EPS on AMPK, AKT, p27 and cyclin E do not indicate arrest in G1, but actually 
suggest that cells have progressed through the G1/S transition after EPS. In order to assess the cell cycle 
profiles of EPS (8V, 48hrs) and non-simulated cells we stained the cells with propidium iodide and 
subsequently measured for DNA content using flow automated cytometry (FACS) (Fig. 3F-H). These cell 
cycle analyses revealed that EPS caused a significant reduction of cells in G1 with a proportional rise of 
cells in G2/M. The proportion of cells within S phase remained unaltered by EPS. 
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Figure 3. EPS does not cause a G1 arrest but rather a G2/M arrest. (A) Western blots of proteins implicated in G1/S phase signaling with 
exception to COX-IV a marker of mitochondria and b-actin which was used as the loading control. (B-E) protein expression relative to non-
stimulated controls. Non-stimulated controls were standardized as 100%. All values are represented as the mean ± S.E.M.; * p<0.05 relative 
to non-stimulated (N = 3-8) (F) Histogram from FACS analysis of PI stained non-stimulated cells. (G) Histogram from FACS analysis of PI 
stained EPS conditioned cells. (H) Comparison of the proportion of cells within G1, S and G2/M between non-stimulated and EPS 
conditioned cells. All values are represented as the mean ± S.E.M.; * p≤0.05 (N = 4) 
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Markers of autophagy are increased following EPS Given the distinct reduction in cell number 
following EPS we analyzed whether cells were entering non-necrotic cell death programs. Prior work on 
RMS cells showed that EPS elevated LC3 protein levels. Since there was no sub-G1 population evident in 
EPS cells measured by FACS (Fig. 3G) initial experiments focused on LC3 and potential modes of cell 
death mediated by autophagic programming. We found that MCF7s exposed to EPS caused drastic 
increases in autophagy markers. EPS increased LC3-I up to 484% after 2 days (10V), an indication of 
autophagy induction (Fig. 4A, upper band, Fig. 4B). Upon autophagy induction LC3-I is converted to LC3-
II (lower band). This conversion is essential for the membrane formation required to form mature 
autophagosomes. EPS drastically increased LC3-II at all voltages reaching a maximum of 746% following 
two days of EPS (Fig. 4C). LC3-I to LC3-II conversion rates (LC3-II/Total LC3) relative to controls were 
also elevated following EPS (Fig. 4D). During autophagy cytoplasmic contents are engulfed inside the 
autophagosome. This engulfment can, and commonly does include the ubiquitin cargo binding protein p62. 
EPS caused a large and rapid increase in p62 protein reaching levels that were 579% greater than those in 
non-stimulated cells after only 1 day of EPS (Fig. 4E).  
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Figure 4. Markers of autophagy are increased following EPS. (A) Western blots of proteins implicated in autophagy with exception to 
b-actin which was used as the loading control. (B-D) protein expression relative to non-stimulated controls. Non-stimulated controls 
were standardized as 100%. All values are represented as the mean ± S.E.M.; * p≤0.05 relative to non-stimulated, # p<0.05 relative to 
all voltages (N = 4-8). 
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EPS may inhibit late stage autophagy Elevations in both of the autophagy markers LC3-II and p62 
suggested that an inhibition of late stage autophagy was occurring and causing a build-up of 
autophagosomes. The lysosomal inhibitor chloroquine (CQ), routinely used to assess autophagic flux, was 
used to assess the status of late stage autophagy. CQ inhibits autophagosome degradation by accumulating 
inside lysosomes and elevating the pH of the otherwise acidic organelle. This elevation inhibits pH 
dependent hydrolytic enzymes required for lysosomal degradation. This allowed us to compare autophagic 
flux in control and EPS cells and assess the contribution of lysosomal degradation to the increase in LC3-
II and p62 observed with EPS. Initial dose response experiments showed that, as expected, CQ increased 
LC3-II proteins levels in non-stimulated cells at 15 µM and 20 µM attaining values that were 395% and 
597% higher than those in DMSO treated cells, respectively (Fig. 5A-B). Surprisingly, CQ failed to increase 
p62 protein levels (Fig. 5C-D), potentially an indication that the autophagy pathway is altered in MCF7 
cells. In addition, CQ had no effect on p62 protein levels in EPS cells (Fig. 5D). At 20 µM by comparing 
the CQ treated EPS group to the CQ treated control group we see that with reduced lysosome function the 
relative difference in LC3-II between EPS and controls is greatly decreased, attributed to the increase in 
LC3-II in non-stimulated CQ treated cells (Fig. 5E-F). In addition, an additive effect of EPS with 15 µM 
and 20 µM of CQ was also evident.  
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Figure 5. EPS may inhibit late stage autophagy. (A) Western blots. b-actin used as the loading control. (B-C) relative protein expression in 
response to increasing concentrations of CQ. All values are relative to the untreated control condition which was standardized as 100%. All 
values are represented as the mean ± S.E.M.; * p<0.05 relative to untreated (N = 5-6) (D-E) relative protein expression in response to increasing 
concentrations of CQ with or without EPS. All values are relative to the untreated control condition which was standardized as 100%. All 
values are represented as the mean ± S.E.M.; * p<0.05 relative to untreated (N = 4) (F) Relative fold above control between the EPS condition 
and its respective control.  All values are relative to the respective control condition which was standardized as 100% and represented as a line 
within each bar. All values are represented as the mean ± S.E.M.; * p≤0.05 relative to the untreated EPS condition (white bar) (N = 3) 
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EPS induced responses in MCF7 cells are Ca+2 dependent Given the importance of Ca2+ signaling 
in excitable cells, the intracellular Ca+2 chelator BAPTA-AM (BAPTA) was used to determine the role of 
Ca2+ in the response of MCF7 cells to EPS. BAPTA appeared to be highly effective in chelating Ca2+ as 
inhibitory effects were visible at concentrations as low as 4 µM. While non-stimulated cells exposed to 12 
µM BATPA alone were able to proliferate and survive, all cells subjected to both EPS and BAPTA 
exhibited obvious cell death by 48 hours post EPS (Fig. 6B). Given that Ca2+ is known to activate AMPK, 
unexpectedly we found that BAPTA caused a dose-depended increase in pAMPKT172 levels (Fig. 6C).  In 
addition, Ca2+ chelation was able to completely abolish the EPS-induced decreases in pAMPKT172.  
Furthermore, BAPTA treatment blunted the EPS-induced reduction in cyclin E protein levels at a 
concentration of 12 µM (Fig. 6D), thereby illustrating a role of Ca2+ in this response.  
The most dramatic effects of EPS and BAPTA were evident for the autophagic proteins LC3-I and p62 
(Fig. 4).  Ca2+ chelation with BAPTA prevented the EPS-dependent increases in LC3-I and p62 protein 
levels in a dose-dependent manner (Fig. 7A-C). These Ca2+-dependent effects were only observed in the 
adaptive response to EPS as BAPTA alone did not alter p62 or LC3 levels in non-stimulated control cells 
(Fig. 7B-D). This suggests that EPS requires Ca2+ for the elevations of p62 and LC3-I. Furthermore, 
BAPTA increased the conversion of LC3-I to LC3-II in response to EPS at 8 and 12 µM demonstrating 
98% and 79% increases above controls, respectively (Fig. 7D). This suggests that EPS and Ca2+ plays a role 
in the processing of LC3 in MCF7 cells in response to EPS. Given that adding CQ did not affect p62 in 
non-stimulated control cells (Fig. 6B), CQ did not alter the p62 response to BAPTA and EPS, as expected. 
This further confirmed that the changes in p62 in response to EPS and BAPTA are independent of lysosome 
function. 
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Figure 6. Ca+2 dependent responses of EPS: cell cycle regulatory proteins. (A) Western blots of proteins implicated in autophagy and G1/S 
phase signaling with exception to b-actin which was used as the loading control. (B-C) protein expression relative to parallel non-stimulated 
controls. Non-stimulated controls were standardized as 100%. All values are represented as the mean ± S.E.M.; * p≤0.05 relative to untreated 
(N = 3-5) (D) Representative brightfield microscopy images of EPS conditioned cells with or without 12 µM BAPTA treatment 48 hours 
following the onset of EPS. 
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Figure 7. Ca+2 dependent responses of EPS: Autophagy regulatory proteins. (A) Western blots of proteins implicated in autophagy signaling 
with exception to b-actin which was used as the loading control. (B-D) protein expression relative to parallel non-stimulated controls. Non-
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Relative p62 expression in response to EPS, CQ and BAPTA. No effect of CQ (20 µM) on blunted EPS elevation of p62 in the presence of 
BAPTA (6 µM) (N = 4). 
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EPS may induce G2/M arrest via p21 independent of p53 p21 induction has been more recently 
associated with autophagic pathways, specifically via Beclin-1 mediated induction182, as well as cell cycle 
arrest typically associated with p5360. Although Beclin-1 was unaffected by EPS (data not shown), we saw 
2-fold increases in p21 (Fig. 8A-B). Despite these increases in p21, there were no effects of EPS evident 
on p53 protein levels (Fig. 8C). This suggests that the increase in p21 may not be due to increased 
transcriptional activation by p53. Additionally, this induction of p21 is unaffected by BAPTA or CQ (Fig. 
8B).  Given that EPS induces a G2/M phase arrest we decided to measure the activation of CDC2 through 
phosphorylation on threonine 161 (CDC2T161), a necessary step for G2 progression which has been shown 
to be mediated through a p21 dependent mechanism62 (Fig. 8D). There were no observable effects of EPS, 
BAPTA, or CQ on the protein levels of CDC2T161 (Fig. 8E).   
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Figure 8. EPS may induce G2/M arrest via p21 independent of p53. (A) Western blots of proteins implicated in G2/M phase signaling 
with exception to b-actin which was used as the loading control. (B-D) protein expression relative to the non-stimulated control. Non-
stimulated controls were standardized as 100%. All values are represented as the mean ± S.E.M.; * p≤0.05 relative to untreated (N = 4-
6) 
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7.5 Discussion  
 
The application of EPS is primarily understood as a mechanism that provokes membrane 
depolarizations in excitable cell types154. However, processes beyond membrane depolarizations within 
excitable cell types are also affected through the application of electrical charge183,184. Furthermore, our lab 
has previously shown both anti-proliferative as well as autophagic effects following the application of low-
frequency alternating currents to non-excitable myoblast and cancerous RMS cells166. These studies lay the 
foundation for our current study where we show that the EPS of MCF7 cells induces novel functional and 
molecular events leading to cell cycle arrest, autophagy reprograming and ultimately the induction of 
proliferative senescence. 
The morphology and reductions in cell numbers following EPS, led us to examine the role of non-
programmed cell death through necrosis. Measurements of LDH within the media affirmed that EPS did 
not elicit significant cytoplasmic damage or necrosis. Furthermore, total LDH measurements following cell 
lysis confirmed that the reductions in cell number following EPS were a result of a decline in cell 
proliferation.  EPS did not seem to activate apoptosis however our observations did show drastic alterations 
in autophagy status. Additionally, there was a clear indication that EPS leads to senescence. Cellular 
senescence is more commonly associated with an initial G1 arrest177–180 however, our results indicated that 
EPS causes a G2/M phase arrest. Within the M phase spindle formation and chromosome separation rely 
heavily on charge dependent processes185,186. In agreement with this, mitotic catastrophe has been observed 
in glioblastoma cells following the application of high-frequency alternating currents183,187. Cells 
undergoing mitosis during and or following EPS may be unable to complete mitotic division leading to the 
stall in mitosis. A stall within M phase agrees with the cell rounding and double nucleated cells seen 
following EPS (Fig. 2). That said, most of the distinct morphological characteristics were manifested 48-
72 hours following the onset of EPS suggesting that EPS sets in motion a programmed response in MCF7 
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cells. Within this timeframe EPS cells enlarge and flatten greatly compared to non-stimulated controls. This 
morphology matched that associated with senescence. Furthermore, after re-plating 48 hours following the 
initiation of EPS, no appreciable cell growth was observed and over the subsequent 4 days monitored, 
regardless of re-plating and the replenishment of media, cell proliferation was absent. Therefore, EPS 
elicited a permanent arrest and loss of re-proliferative potential both of which are characteristic of 
senescence. Thus, the enlarged and flattened morphology, proliferative arrest and increased positive SA-ß-
gal staining indicate strongly that the proliferative failure seen in cells initiated by EPS does indeed lead to 
cellular senescence. Specific prerequisites to cellular senescence have been shown to require cell 
enlargement and cell cycle arrest in a process that has been recently termed geroconversion188,189. This 
process involves a loss of re-proliferative potential and the formation of a hypertrophic phenotype. The 
associated hypertrophic phenotype (enlarged and flattened) and loss of re-proliferative potential has been 
shown to be driven by mTOR activity during arrest188. EPS induces robust increases in AKT activation, 
which strongly indicates the downstream activation of mTOR that could drive the hypertrophic phenotype 
observed in EPS cells. Furthermore, it has been shown that in some cell types AMPK suppresses 
geroconversion in an effort to maintain quiescence through mTOR inhibtion190. Here we show substantial 
reductions in AMPK activation following EPS. This further supports a mechanism of mTOR activation 
leading to the hypertrophic phenotype observed following EPS.  
To attain senescence the cell also requires an initial arrest. One of the main biomarkers in cell cycle 
arrest leading to senescence is p21 induction191. Here we show sustained two-fold increases in p21 
following only a single bout of EPS. In agreement with results in RMS cells and the protein expression 
patterns observed in this study (no change in p27 and decreases in cyclin E protein levels) cells subjected 
to EPS demonstrated a phenotype suggestive of a transition through G1/S. Additionally, AMPK activation 
has been shown to arrest MCF7 cells in G1181 thus the EPS dependent reductions in AMPK activation further 
supported the idea that EPS did not elicit a G1 arrest and thus further suggested a G2/M arrest prior to 
senescence. FACs analysis confirmed this theory showing an accumulation of cells in G2/M following EPS. 
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That said, more work is needed to fully elucidate the precise location and mechanism of EPS induced cell 
cycle arrest within G2/M.  
Autophagy reprogramming in response to EPS was initially observed in experiments using RMS cells 
with elevations in the autophagy protein marker LC3166. Here we confirmed these results, with EPS yielding 
dose dependent elevations in total LC3 protein content across voltages with 3-fold increases in LC3-I and 
7-fold increases in LC3-II, respectively. LC3-I conversion to LC3-II is a critical event in autophagosome 
formation and is a commonly used marker for this process104. However, elevations in LC3-II and 
autophagosome content can be attributed to a complex balance of multiple synthesis and degradation events 
and are not solely indicative of changes in autophagy flux. By using the lysosomal inhibitor CQ, we were 
able to assess the status of autophagy flux following EPS. In response to EPS the pool of LC3-II rose 2.4-
fold above non-stimulated controls. This relative 2.4-fold increase in LC3-II was reduced with the inhibition 
of the lysosome. The compression of the relative difference between control and EPS conditioned cells in 
the presence of CQ indicates that the pool of LC3-II formed in response to EPS may be the result of a 
similar inhibitory event within the autophagy pathway. However, EPS consistently showed an additive 
effect to pharmacological lysosome inhibition with a consistent absolute difference of approximately 200% 
across all CQ concentrations. Higher concentrations of CQ are required to ensure complete inhibition of 
the lysosome in order to gain a clearer understanding of specifically how EPS-dependent effects on 
autophagy flux are elicited. 
 Autophagy has been shown to be upregulated within chemotherapy resistant tumors121, furthermore, 
the late stage inhibition of autophagy through the use of CQ has been shown to improve patient outcomes 
by eliminating the chemotherapy resistance conferred through autophagy116,117,122–125. Therefore, EPS may 
then serve a similar purpose via a localized stimulus, which can potentially mitigate the systemic issues 
associated with drug treatments such as CQ. Additionally, we show an association of proliferative failure 
and autophagy inhibition that agrees with prior observation of various breast cancer cell lines exposed to 
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silencing mRNA of autophagy regulating genes119. Interestingly, most cancerous cell lines showed more 
drastic reductions in cell number compared to non-cancerous breast cell lines suggesting a potential cancer-
specific targeting effect of EPS. 
 Surprisingly, the cargo-sequestering protein p62, which can be localized inside autophagosomes, 
responded to EPS but not CQ in MCF7 cells. The lack of response of p62 to CQ implies that elevations in 
p62 following EPS are independent of the autophagosome, supporting the idea that p62 and/or autophagy 
regulation is somehow altered in MCF7 cells. It is worth noting that p62 has multiple functions outside of 
autophagosomes including the regulation of CDC271,193,194, influence within proteostasis108,195 and an 
additional mechanism of mTORC1196 activation. The elevation of p62 in the EPS response may then serve 
any number of these additional functional roles.  
The established effects of low frequency electrical current point to membrane depolarization events 
leading to the release of calcium stores into the cytoplasm155. Although MCF7 cells lack the vast 
sarcoplasmic calcium storage capacity of myotubes, they still do contain substantial stores, the most notable 
of which being within the endoplasmic reticulum197. Thus, we assessed the role of Ca2+ using the membrane 
permeable calcium chelator BAPTA-AM. MCF7 cells were highly sensitive to BAPTA with effects 
observed at concentrations as low as 4 µM. Following EPS, BAPTA did not mitigate the anti-proliferative 
effects of EPS but did cause distinct morphological changes associated with cell death which were most 
prominent at 12 µM BAPTA. While non-stimulated cells exposed to 12 µM BAPTA alone were able to 
proliferate and survive, all cells subjected to both EPS and BAPTA exhibited obvious cell death by 48 hrs. 
Interestingly, we also found a dose dependent decline in the EPS dependent elevations of LC3-I and p62. 
No such effect was seen in non-stimulated cells exposed to BAPTA alone suggesting that Ca2+ is involved 
in the adaptive but not baseline regulation of LC3-I and p62. The lack of effect of co-treatment with BAPTA 
and CQ further confirmed that the p62 protein response is autophagosome and lysosome independent. 
Previous studies have shown that the accumulation of protein aggregates containing p62 and LC3-I form 
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under conditions of autophagic impairment that are implicated in cell survival and senscence105,171–173,198, a 
response similar  to that described herein following EPS. Our results suggest that Ca2+ EPS-dependent p62 
and LC3-I elevations may be associated with a pro-survival response since EPS in the presence of BAPTA 
elicits massive cell death. However, the precise mechanism of action requires further study to completely 
map out the potential roles of p62 and LC3-I in cell survival. With EPS, we observed an overall increase in 
conversion rates between LC3-I and LC3-II which were further increased following calcium chelation. CQ 
experiments revealed that LC3-II looks to be accumulating due to an inhibition of late stage autophagic 
degradation however the additive effect of EPS in the presence of CQ may be contributed to EPS-dependent 
elevations in LC3 conversion. Calcium induced events following EPS look to elevate LC3-I in an autophagy 
independent manner which may be masking the elevation in conversion rate under EPS only conditions 
(Fig. 9).   
Overall, we show that EPS sets in motion a programmed proliferative failure leading to senescence 
which requires cell cycle arrest in G2/M, in what may be a p53 independent manner. We also show that EPS 
drastically increases the autophagy markers LC3 and p62 in a mechanism that is mediated in a calcium-
dependent fashion, while also inhibiting the late stages of autophagy through a calcium-independent 
mechanism. The simultaneous reprogramming of autophagy and proliferative pathways makes the EPS of 
MCF7 cells an interesting model of study in the intersection of these two emerging mechanisms. Both 
mTOR signaling and proteostasis serve as particular points of interest for future investigation as they may 
serve as a central point of regulation between autophagy, growth signaling, and cell survival in senescent 
programming. These results also provide a framework for the application of EPS to other cancer cell types, 
with the ultimate goal of developing a novel localized cancer therapy that can both induce permanent arrest 
while sensitizing tumors to chemotherapy.  
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Figure 9. Working Model of EPS-Dependent Proteostasis. EPS elicited both calcium dependent and Ca2+ independent effects. Ca2+ dependent effects 
included the elevation of LC3-I and p62. In the presence of Ca2+ chelation LC3-I and p62 elevations are abolished. Our results are in line with the current 
literature that details p62 dependent LC3-I binding, independent of autophagosomes within protein aggregates, in the presence of autophagic 
impairment105,170–172. Ca2+ independent EPS effects looks to include an impairment of the late stages of autophagy leading to the accumulation of 
autophagosome associated LC3-II. Excessive protein aggregate formation may be the result of cell cycle arrest in the presence of a hypertrophic 
phenotype, both of which have been shown as critical events in cellular senescence187. (?) indicate areas of interest for future investigation. 
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8.0 Limitations & Future Directions  
 
Cell survival and the integrated response Our study indicates that in response to EPS, p62 may play roles 
outside of autophagosomes. The elevations of p62 in response to EPS may also serve as a survival 
mechanism. This hypothesis is based off the distinct elevations in cell death seen in cells treated with EPS 
and BAPTA; a treatment condition which concomitantly abolishes the p62 EPS response. Furthermore, 
the silencing of p62 has been shown to cause conditions of cell death in various cell types105,198. The 
mechanism of cell death under EPS and BAPTA is still unknown however an assessment of caspase 
cleavage products via western blotting are a good initial point of assessment for future research. It is 
becoming increasingly clear that mTOR and p62 are likely to have a critical impact on the functional 
effects observed here. mTOR has been shown to be activated in response to p62196 and AKT89 elevations, 
both of which are involved in cell survival, thus mTOR serves as a central point of regulation. mTOR not 
only links cell growth, survival and senescence but it also has localized effects at the lysosomal 
membrane with its co-activator Rheb90,199. Thus, the lysosome as well as its function serves as another 
point of contact between autophagy, survival and senescent programming that may be linked through 
mTOR.  
Additional experiments of interest include the use of a proteasome inhibitor to assess if the regulation of 
p62 following EPS as well as EPS and BAPTA-AM is mediated though the ubiquitin proteasome 
pathway. Lastly, the source of calcium induced events is an area of interest. The largest calcium store in 
MCF7s is the ER. ER calcium channel inhibitors such as thapsigargin serve as an interesting experiment 
to initially assess the role of the ER in the calcium induced events of EPS.  
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Cell Types and In-Vivo Studies – MCF7s contain some unique characteristics in both autophagy and 
calcium signaling regulation. MCF7s contain a single chromosome deletion of beclin-1200 creating further 
inquiry into whether MCF7s contain any other dysfunctions in autophagy pathways. Furthermore, the 
sarco-/endoplasmic reticulum Ca2+-ATPase (SERCA3), a critical regulator of the influx of calcium into 
the ER is greatly reduced in MCF7s suggesting the calcium handling capabilities at the level of the ER 
may have an attributable contribution to the autophagy effects seen in response to EPS201–203. A previous 
study compares the growth rates of both normal and cancerous breast cell lines with the added inhibition 
of autophagy120. Interestingly, non-cancerous MCF10As had relatively unaffected proliferation rate 
compared to MCF7s. Furthermore, MCF7s in comparison to other breast cancer cell lines were far less 
affected by autophagy reprogramming. Thus, whether or not the responses of EPS outlined here are 
unique to MCF7s or carries over to other non-excitable cell lines such as non-cancerous MCF-10As and 
other cancerous cell types such as prostate LNCaP cells is an area of interest for future study. 
Additionally, whether or not these effects can be carried over into 3D cultures and in-vivo models is 
another area of interest. The groundwork for such a study has yet to be developed. Questions as to how 
EPS can be administrated in-vivo and the effects of electrical impedance while stimulating a three-
dimensional tumor remain to be answered. That said, in-vivo electrical stimulation has been applied and 
well documented within a live rat model to study phenotypic alterations in response to chronic contractile 
activity in skeletal muscle204. Additionally, developing and subjecting chemo resistant cell lines to EPS is 
another avenue of interest for future studies.  The effects of late stage autophagy inhibition in response to 
EPS provide an exciting avenue for the potential ability of EPS to sensitize cells to chemotherapy as it has 
been shown that tumors are able to induce autophagy as a mechanism to resist chemotherapy. Future 
experiments of interest would combine EPS and chemotherapy with the hypothesis that cells exposed to 
EPS will be more sensitive to lower doses of chemotherapy than non-stimulated cells. 
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The Mechanism of Action and EPS Conditioned Media – The exact EPS mechanism of action is yet to 
be understood. At the conclusion of experiments, it was brought to our attention the contribution of EPS 
conditioned media versus the effects of EPS alone205. Following EPS, it became noticeable that the media 
was discolored relative to controls. The interest in the effects of EPS on the media conditions became 
fully apparent when measuring background LDH values. Our media is supplemented with FBS that 
contains LDH. Naturally this background LDH needed to be measured and subtracted. Due to the 
discoloration in the EPS conditioned media we decided measure two backgrounds, one of the media and 
the other of media stimulated in the absence of cells. The LDH values from the conditioned media 
stimulated without cells showed an approximant 50% reduction in LDH content on each stimulation. This 
further brought into question the contribution of the potential denaturation and or cytotoxicity of the 
media on the cells following EPS. Initial experiments were done using the established protocol of a 4-
hour EPS at 8V with a 20-hour rest period however, this time the media was replaced immediately 
following EPS. Furthermore, a small subset of experiments was performed where media alone was 
stimulated and then added to cell cultures. These cells were monitored for 72 hours and collected and 
analyzed via western blotting. Within the EPS conditioned media group (cells cultured in stimulated 
media), the ‘hallmarks of EPS’, reduced growth rate and enlarged flattened morphology were present. 
The EPS conditioned media group also saw elevations in LC3 and p62 as well as a reduction in pAMPK 
levels relative to untreated cells. Additionally, the previously observed effects were reduced with the 
replacement of media following EPS. These initial experiments indicate a definite effect of EPS 
conditioned media however, cell exposed to EPS conditioned media seem to recover whereas cells 
exposed to EPS do not. This has obvious implications on the practical applications of EPS as denaturation 
and or cytotoxicity of the media due to EPS can be attributed as an artifact of culture conditions that may 
not have relevance in-vivo. That said, studies on the effects of EPS conditioned media requires further 
study to clearly dissociate the contribution of EPS mediated effects from EPS conditioned media effects 
and elucidate the mechanism of action occurring with EPS. 
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